Platinum-Resistant Disease
Q&A: ‘Promising’ immunotherapies may treat platinum-resistant ovarian cancer
During their lifetime, one in 70 women will receive a diagnosis of ovarian cancer, which is the second most common gynecologic cancer in the United States, according to Memorial Sloan Kettering Cancer Center.
Relacorilant regimen prolongs survival in recurrent platinum-resistant ovarian cancer
CHICAGO — Intermittent relacorilant plus nab-paclitaxel demonstrated an OS benefit among women with recurrent platinum-resistant/refractory ovarian cancer compared with nab-paclitaxel alone.
Mirvetuximab soravtansine shows antitumor activity in platinum resistant ovarian cancer
Mirvetuximab soravtansine demonstrated efficacy and tolerability in patients with platinum resistant ovarian cancer, according to phase 3 clinical data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Mirvetuximab soravtansine active in previously treated ovarian cancer
Mirvetuximab soravtansine induced confirmed objective response in about one-third of women with folate receptor alpha-high platinum-resistant ovarian cancer who previously received bevacizumab, according to the agent’s manufacturer.
FDA grants fast track designation to STRO-002 for advanced gynecologic cancers
The FDA granted fast track designation to STRO-002 for treatment of certain women with advanced gynecologic cancer.
FDA grants fast track designation to XMT-1536 for ovarian cancer subset
The FDA granted fast track designation to XMT-1536 for the treatment of women with high-grade serous ovarian cancer, according to a press release from the agent’s manufacturer.